Let’s Talk About Resilience

Psychiatric TimesVol 37, Issue 4
Volume 37
Issue 4

Psychiatry is in a unique position to help the world navigate these unprecidented times. MJH Life Sciences' founder and CEO introduces the newest issue of Psychiatric Times.


As I write this, the world is dealing with an unprecedented crisis. COVID-19 is not only affecting us in terms of our health, but it is also having a huge impact on the global economy and our everyday lives. Psychiatry is in a unique position to help the world navigate these times.

Psychiatry’s focus on recovery and resilience allows for a positive approach to challenges. Psychiatrists have been on the forefront of dealing with disasters and learning from them, so they can not only help their patients but society as a whole. Along those lines, Phebe Tucker, MD, shares a poignant perspective on resilience in her article commemorating the Oklahoma City bombing.

Similarly, Harold J. Bursztajn, MD, shares stories of resilience during another tragic time in our history-the Holocaust. His reflections and commentary remind us that the right attitude sprinkled with hope can make a huge difference in our survival during the most horrific times. I concur that resilience, not panic, is key in this time of pandemic.

And so, we continue to march forward, meeting our daily challenges despite this new crisis. Your patients continue to need care, perhaps now more than ever, and Psychiatric Times is here to support you in that endeavor.

David Osser, MD, sheds light on the growing use and normalization of medical marijuana in patients with bipolar disorder. Did you know that 25% to 30% of patients with Parkinson disease have psychotic symptoms? Rajesh R. Tampi, MD, and Deena J. Tampi, RN, discuss the underlying pathophysiology, assessment, and management of these symptoms. Stephen A. Wyatt, DO, delves into world of benzodiazepines, exploring their mechanism of action and how to make treatment decisions. Although there has been some controversy and concern regarding this class of medications, they can be helpful if used cautiously and appropriately.

You will also find our Special Report on Sleep Disorders and some of our regular features to support you in your practice. And, don’t forget to check out our special coverage of COVID-19 online at www.psychiatrictimes.com.
We hope you and yours remain safe, well, and resilient during these challenging times!

Mike Hennessy Sr
Chairman and Founder, MJH Life Sciences, parent company of Psychiatric Times

Related Videos
Video 2 - "Narcolepsy Evaluation, Management, and Treatment Considerations"
Video 2 - "Diagnostic Practices for Narcolepsy"
Video 6 - "Future Perspectives on Schizophrenia Care"
Video 2 - "Pathophysiology of Narcolepsy and the Role of Orexins"
Video 1 - "Definition of Narcolepsy and Unmet Needs"
Erin Crown, PA-C, CAQ-Psychiatry, and John M. Kane, MD, experts on schizophrenia
© 2024 MJH Life Sciences

All rights reserved.